Literature DB >> 9762901

Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity.

T Sasaki1, M Costell, K Mann, R Timpl.   

Abstract

Glycosaminoglycan attachment to perlecan domain I (173 residues) was completely prevented by site-directed mutagenesis of Ser-65, Ser-71 and Ser-76 as shown by recombinant production in mammalian cells. This did not interfere with the proper folding of the domain's SEA module but enhanced its sensitivity to neutral proteases. Lack of substitution also abolished binding to the two major heparin binding sites of laminin-1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9762901     DOI: 10.1016/s0014-5793(98)01063-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins.

Authors:  J F Talts; Z Andac; W Göhring; A Brancaccio; R Timpl
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

2.  Beta1 integrin and alpha-dystroglycan binding sites are localized to different laminin-G-domain-like (LG) modules within the laminin alpha5 chain G domain.

Authors:  Hao Yu; Jan F Talts
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

3.  Perlecan-stimulated nodules undergo chondrogenic maturation in response to rhBMP-2 treatment in vitro.

Authors:  Ronald R Gomes; Mary C Farach Carson; Daniel D Carson
Journal:  Connect Tissue Res       Date:  2003       Impact factor: 3.417

Review 4.  Amyloid accomplices and enforcers.

Authors:  Andrei T Alexandrescu
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

Review 5.  Extracellular matrix and heart development.

Authors:  Marie Lockhart; Elaine Wirrig; Aimee Phelps; Andy Wessels
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-05-25

Review 6.  Genetic variants of mucins: unexplored conundrum.

Authors:  Sushil Kumar; Eric Cruz; Suhasini Joshi; Asish Patel; Rahat Jahan; Surinder K Batra; Maneesh Jain
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

7.  Comparative characterisation of recombinant invertebrate and vertebrate peptide O-Xylosyltransferases.

Authors:  Andrea Brunner; Daniel Kolarich; Josef Voglmeir; Katharina Paschinger; Iain B H Wilson
Journal:  Glycoconj J       Date:  2006-11       Impact factor: 2.916

8.  Perlecan displays variable spatial and temporal immunolocalisation patterns in the articular and growth plate cartilages of the ovine stifle joint.

Authors:  James Melrose; Susan Smith; Martin Cake; Richard Read; John Whitelock
Journal:  Histochem Cell Biol       Date:  2005-06-17       Impact factor: 4.304

9.  Perlecan: an important component of the cartilage pericellular matrix.

Authors:  R Gomes; C Kirn-Safran; M C Farach-Carson; D D Carson
Journal:  J Musculoskelet Neuronal Interact       Date:  2002-12       Impact factor: 2.041

10.  Ribozyme-mediated perlecan knockdown impairs chondrogenic differentiation of C3H10T1/2 fibroblasts.

Authors:  Ronald R Gomes; Sonali S Joshi; Mary C Farach-Carson; Daniel D Carson
Journal:  Differentiation       Date:  2006-02       Impact factor: 3.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.